Stock Events

Immunovia AB 

SEK1.52
0
+SEK0+0% Monday 08:06

Statistics

Day High
1.52
Day Low
1.52
52W High
7.83
52W Low
0.99
Volume
7,631
Avg. Volume
21,015
Mkt Cap
191,012
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

10NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.25
-0.2
-0.15
-0.1
Expected EPS
N/A
Actual EPS
-0.096

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0G8X.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Exact Sciences
EXAS
Mkt Cap8.55B
Exact Sciences Corp. offers cancer screening and diagnostic tests, competing directly in the early detection market where Immunovia also operates.
Guardant Health
GH
Mkt Cap3.8B
Guardant Health provides liquid biopsy tests for cancer diagnostics, overlapping with Immunovia's focus on early cancer detection using blood-based biomarkers.
Roche
RHHBY
Mkt Cap200.6B
Roche Holding AG develops diagnostic tools and technologies for detecting various diseases including cancer, similar to Immunovia's diagnostic solutions.
Illumina
ILMN
Mkt Cap18.49B
Illumina, Inc. offers genomic sequencing solutions used in cancer and other health diagnostics, competing in the broader market of molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap9.63B
Qiagen N.V. provides sample and assay technologies for molecular diagnostics, competing with Immunovia in the field of precision medicine and diagnostics.
Quest Diagnostics
DGX
Mkt Cap16.01B
Quest Diagnostics incorporates advanced diagnostics for conditions including cancer, directly competing with Immunovia's diagnostic tests.
Bio-Rad Laboratories
BIO
Mkt Cap8.57B
Bio-Rad Laboratories, Inc. specializes in clinical diagnostics and life science research, offering products that compete in the diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap626.91M
Fulgent Genetics, Inc. focuses on genetic testing to detect cancer and other diseases, competing with Immunovia's genomic and proteomic testing approaches.
Myriad Genetics
MYGN
Mkt Cap2.39B
Myriad Genetics, Inc. provides molecular diagnostic tests that assess the risk of developing cancer, competing with Immunovia's focus on early detection and risk assessment.

About

Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Show more...
CEO
Mr. Philipp Mathieu
Employees
39
Country
SE
ISIN
SE0006091997
WKN
000A2AG0F

Listings